Influence of Experimental End Point on the Therapeutic Efficacy of Essential and Additional Antidotes in Organophosphorus Nerve Agent-Intoxicated Mice

Jiri Kassa 1,*, Christopher M. Timperley 2, Mike Bird 2, A. Christopher Green 2 and John E. H. Tattersall 2

1 Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, 60200 Brno, Czech Republic
2 Chemical, Biological and Radiological Division, Defence Science and Technology Laboratory (DSTL), Salisbury SP4 0JQ, UK; cmtimperley@mail.dstl.gov.uk (C.M.T.); mbird@dstl.gov.uk (M.B.); acgreen@dstl.gov.uk (A.C.G.); jtattersall@dstl.gov.uk (J.E.H.T.)

* Correspondence: kassa@pmfhk.cz; Tel.: +420-973255164

Abstract: The therapeutic efficacy of treatments for acute intoxication with highly toxic organophosphorus compounds, called nerve agents, usually involves determination of LD_{50} values 24 h after nerve agent challenge without and with a single administration of the treatment. Herein, the LD_{50} values of four nerve agents (sarin, soman, tabun and cyclosarin) for non-treated and treated intoxication were investigated in mice for experimental end points of 6 and 24 h. The LD_{50} values of the nerve agents were evaluated by probit-logarithmical analysis of deaths within 6 and 24 h of i.m. challenge of the nerve agent at five different doses, using six mice per dose. The efficiency of atropine alone or atropine in combination with an oxime was practically the same at 6 and 24 h. The therapeutic efficacy of the higher dose of the antinicotinic compound MB327 was slightly higher at the 6 h end point compared to the 24 h end point for soman and tabun intoxication. A higher dose of MB327 increased the therapeutic efficacy of atropine alone for sarin, soman and tabun intoxication, and that of the standard antidotal treatment (atropine and oxime) for sarin and tabun intoxication. The therapeutic efficacy of MB327 was lower than the oxime-based antidotal treatment. To compare the 6 and 24 h end points, the influence of the experimental end point was not observed, with the exception of the higher dose of MB327. In addition, only a negligible beneficial impact of the compound MB327 was observed. Nevertheless, antinicotinics may offer an additional avenue for countering poisoning by nerve agents that are difficult to treat, and synthetic and biological studies towards the development of such novel drugs based on the core bispyridinium structure or other molecular scaffolds should continue.

Keywords: atropine; MB327; nerve agents; oximes; mice

1. Introduction

Organophosphorus nerve agents are highly toxic chemical warfare agents. Their signs and symptoms can appear rapidly [1]. They inhibit acetylcholinesterase (AChE, EC 3.1.1.7) irreversibly [2]. Acetylcholine (ACh) then accumulates in the nervous system. The ACh overstimulates muscarinic (mAChRs) and nicotinic acetylcholine receptors (nAChRs) causing muscarinic and nicotinic effects: muscle twitching, lachrymation, miosis, salivation, seizures and coma [3]. Death arises from the inability to breathe, bronchial spasm and hypersecretion, and paralysis of the diaphragm and the brain respiratory centers [4,5].

The acute poisoning is usually treated by injecting a reactivator of the inhibited AChE (such as pralidoxime, HI-6, obidoxime or trimedoxime), an antimuscarinic (usually atropine to counter the muscarinic effects) and an anticonvulsant (e.g., diazepam to counter the centrally-mediated seizures) [1–5]. The treatment does not include drugs able to directly reduce the nicotinic effects. Its effectiveness is generally insufficiently broad because of the limitation of a single oxime to reactivate AChE inhibited by all nerve agents equally [6–8].
The search for more efficient therapies continues [9–11]. One option is to use an nAChR antagonist to counter the nicotinic effects [12]. Nicotinic antagonists administered with the aforementioned standard drug combination can help [13] as atropine cannot reverse the nerve agent-induced overstimulation of nAChRs [14]. Some bispyridinium compounds can do this, by blocking the nAChR open ion channel and/or orthosteric sites, or by positive allosteric modulation of nAChRs [15–20].

The bispyridinium non-oxime [1,1’-(propane-1,3-diyl) bis(4-tert-butyl pyridinium) diiodide] (MB327) was prepared at Dstl Porton Down, Salisbury, United Kingdom, and was found to be effective for treating the actions of nerve agents in guinea pigs [21,22]. MB327 has been shown to have a positive therapeutic effect due to a non-competitive action at muscle type nAChRs and positive allosteric activity at neuronal nAChRs [20].

MB327 is more effective over shorter timescales due its rapid elimination from the circulation (in guinea pigs) [23]. The therapeutic efficacy of antidotes is most often investigated 24 h after the nerve agent challenge. However, given that clearance of the treatment drugs, including MB327 and atropine, may impact their efficacy, the use of an earlier end point may provide a more realistic or useful assessment of their benefit as immediate or first aid treatments.

The present study measured the 6 h LD$_{50}$ of sarin, soman, tabun or cyclosarin in mice either alone, or in the presence of atropine with or without an effective oxime (HI-6, obidoxime or trimedoxime) and/or MB327 (Figure 1). The results were compared to the 24 h LD$_{50}$ measurements.

![Figure 1](image-url)  
**Figure 1.** Components (**A**) of the therapies tested—the antimuscarinic atropine, the oximes HI-6, obidoxime and trimedoxime, and the antinicotinic MB327—against the panel of nerve agents shown (**B**).

2. **Materials and Methods**

2.1. **Animals**

Male NMRI mice aged 7 weeks, weighing 30–35 g from VELAZ (Prague, Czech Republic) were housed in polypropylene solid bottom cages in climate- and access-controlled rooms (22 ± 2 °C and 50 ± 10% relative humidity) with light from 07:00 to 19:00 h and access to standard food and tap water ad libitum. The mice were acclimatized in the laboratory vivarium for 14 days before the experiments commenced. They were divided into groups of 6 animals and handled under the supervision of the Ethics Committee of the Faculty of Military Health Sciences in Hradec Kralove (Czech Republic).
2.2. Chemicals

The nerve agents were obtained in 85–90% purity (by acidimetric titration) from the Military Technical Institute in Brno (Czech Republic). Stock solutions of these (1 mg/mL) were prepared in propylene glycol 3 days before starting the experiments. The solutions were diluted with saline immediately before administration. HI-6, obidoxime and trimedoxime dichlorides were synthesized in the Department of Toxicology and Military Pharmacy of the Faculty of Military Health Sciences in Hradec Kralove. Their purity was assessed by high performance liquid chromatography (HPLC) with ultraviolet detection (310 nm) and exceeded 95% [24]. MB327 of 99% purity was synthesized at Dstl Porton Down [22]. Other chemicals of a similar analytical grade were purchased commercially and used as received. All substances were administered by intramuscular (i.m.) injection at a volume of 10 mL/kg body weight (b.w.). The volume of administered substances was higher than recommended for i.m. administration in mice but there were no adverse effects observed.

2.3. In Vivo Experiments

The LD\textsubscript{50} values of the nerve agents and 95% confidence limits in mice were evaluated by probit-logarithmical analysis of deaths within 6 and 24 h of i.m. administration of the nerve agent at 5 different doses, using 6 mice per dose [25]. The intoxicated mice were treated i.m. with atropine or with an oxime and/or MB327. An effective oxime was used for each nerve agent: obidoxime for sarin, trimedoxime for tabun, and HI-6 for soman and cyclosarin [4,7,26,27].

The oximes were delivered at equitoxic doses (obidoxime 5.8 mg/kg; trimedoxime 5.3 mg/kg; and HI-6 at 25 mg/kg) corresponding to 5% of their respective LD\textsubscript{50}. MB327 was administered at doses (16.7 and 33.4 mg/kg) corresponding to 10 and 20% of its respective LD\textsubscript{50} [22]. Equitoxic doses were used to ensure that sufficiently safe doses with respect to their different toxicities were given. Consistent with previous work, atropine (10 mg/kg) was injected at a dose approximating 2% of its LD\textsubscript{50} [28]. All antidotes were applied as an admix 1 min after i.m. administration of the nerve agent.

The LD\textsubscript{50} values of the nerve agents and 95% confidence limits in mice treated with the antidotes were evaluated by the method used to determine the toxicity of the nerve agents without antidotal treatment [25]. The therapeutic efficacy of the antidotal combinations was expressed as a protective ratio A (LD\textsubscript{50} value of the nerve agent in protected mice/LD\textsubscript{50} value of the nerve agent in unprotected mice) for the 6 or 24 h end points. The influence of end point on the therapeutic efficacy of the antidotes was expressed as a protective ratio B (LD\textsubscript{50} value of the nerve agent in mice for the 6 h end point/LD\textsubscript{50} value of the nerve agent in mice for the 24 h end point). Statistical significance was determined by a one-way ANOVA test with Tukey’s post hoc test and differences were considered significant when \( p < 0.05 \) [25].

3. Results

Clinical signs in mice intoxicated with sarin, soman, tabun and cyclosarin included salivation, lachrymation, nasal secretion and tonic-clonic convulsions. Signs were observed within a few minutes of administration of the nerve agents. In the case of treatment for nerve agent poisoning, nerve agent-induced signs and symptoms did not disappear but their intensity was decreased regardless of the type of nerve agent used. The decrease in the intensity of toxic signs and symptoms was especially observed when atropine in combination with an oxime was used as a treatment of nerve agent poisoning. Observations and potencies of the antidotes studied are now discussed in turn.

3.1. The Efficacy of Antidotes (Atropine, Obidoxime, MB327) for Prevention of Sarin Lethality

The dependence of the therapeutic efficacy of the various combinations of treatments on the selected experimental end point is summarized in Table 1. The times to death were similar for all treatment groups. Most mice died within the first hour. The average time
to death within the first 6 h was 7.4 min for non-treated animals and 8.1 min for treated animals. Only in the atropine alone group did some deaths occur after 6 h. All deaths occurred within 6 h of intoxication for the other groups: atropine with obidoxime or MB327, and atropine with obidoxime and MB327. Atropine increased the LD$_{50}$ of sarin 1.25-fold at 6 h and 1.10-fold at 24 h. The combination of atropine and obidoxime increased it 1.45-fold. With the lower dose of MB327, it increased it 1.21-fold, and with the higher dose of MB327 it increased it 1.23-fold. Atropine and obidoxime and the higher dose of MB327 increased it 1.80-fold, regardless of the end point. The efficacy of atropine and obidoxime was higher than that of atropine and MB327 regardless of the dose of the latter. With atropine and MB327, a slight increase in protection ratio versus atropine alone was seen at 24 h but the difference was not significant. A significant benefit of MB327 on the efficacy of atropine and obidoxime was not observed.

Table 1. The effect of experimental endpoint on the protection provided against lethal effects of sarin in mice.

| Treatment                      | LD$_{50}$ (µg/kg) ± 95% Confidence Limit—6 h | Protective Ratio A | LD$_{50}$ (µg/kg) ± 95% Confidence Limit—24 h | Protective Ratio A | Protective Ratio B |
|--------------------------------|---------------------------------------------|------------------|---------------------------------------------|------------------|------------------|
| ———                           | 328.2 (270.1–360.2)                         | —                | 328.2 (270.1–360.2)                         | —                | —                |
| Atropine                       | 411.9 (329.9–514.2)                         | 1.25             | 361.2 (324.9–430.7)                         | 1.10             | 1.14             |
| Atropine + obidoxime           | 476.9 (375.8–539.1) *                       | 1.45             | 476.9 (375.8–539.1) *                       | 1.45             | 1.00             |
| Atropine + MB327 (lower dose)  | 397.8 (354.1–446.8)                         | 1.21             | 397.8 (354.1–446.8)                         | 1.21             | 1.00             |
| Atropine + MB327 (higher dose) | 402.7 (269.1–496.3)                         | 1.23             | 402.7 (269.1–496.3)                         | 1.23             | 1.00             |
| Atropine + obidoxime + MB327   | 591.6 (456.9–766.1) *                       | 1.80             | 591.6 (456.9–766.1) *                       | 1.80             | 1.00             |

* $p < 0.05$ (comparison with the untreated values). Bold values are significantly different from untreated values at the level of $p < 0.05$.

3.2. The Efficacy of Antidotes (Atropine, HI-6, MB327) for Prevention of Soman Lethality

The data for soman appear in Table 2. The times to death differed slightly between the treatment groups; nevertheless, most mice died within the first hour. The average time to death within the first 6 h was 6.7 min for non-treated animals and 22.4 min for treated animals. Only for atropine with the higher dose of MB327 did deaths occur after 6 h. Thus, with the higher dose of MB327 the LD$_{50}$ of soman was increased 1.48-fold at 6 h, but only 1.31-fold at 24 h. In the other groups—atropine alone, or with HI-6 or the lower dose of MB327, or with HI-6 and the higher dose of MB327—all deaths occurred within 6 h. Atropine increased the LD$_{50}$ 1.36-fold, atropine and HI-6 increased it 1.81-fold, atropine and the lower dose of MB327 increased it 1.32-fold, and atropine and HI-6 with a higher dose of MB327 increased it 1.80-fold, at both end points. The efficacy of HI-6 with atropine exceeded that of atropine and MB327 regardless of the MB327 dose and end point. With atropine and the higher dose of MB327, a small increase in protection ratio compared to atropine alone was apparent at 6 h but the difference was not significant. A significant benefit of MB327 on the efficacy of atropine and HI-6 was not observed.
Table 2. The effect of experimental endpoint on the protection provided against the lethal effects of soman in mice.

| Treatment               | LD₅₀ (µg/kg) ± 95% Confidence Limit—6 h | Protective Ratio A | LD₅₀ (µg/kg) ± 95% Confidence Limit—24 h | Protective Ratio A | Protective Ratio B |
|-------------------------|----------------------------------------|--------------------|------------------------------------------|--------------------|--------------------|
| ——                     | 110.5 (79.4–137.1)                    | ——                | 110.5 (79.4–137.1)                       | ——                | ——                |
| Atropine                | 150.1 (92.8–190.1)                     | 1.36              | 150.1 (92.8–190.1)                       | 1.36              | 1.00              |
| Atropine + HI-6         | 199.9 (140.6–282.3) *                  | 1.81              | 199.9 (140.6–282.3) *                    | 1.81              | 1.00              |
| Atropine + MB327 (lower dose) | 145.7 (124.7–186.0)            | 1.32              | 145.7 (124.7–186.0)                      | 1.32              | 1.00              |
| Atropine + MB327 (higher dose) | 163.1 (137.6–225.5) *        | 1.48              | 144.4 (117.9–196.8)                      | 1.31              | 1.13              |
| Atropine + HI-6 + MB327 | 198.8 (158.4–248.3) *                 | 1.80              | 198.8 (158.4–248.3) *                    | 1.80              | 1.00              |

* p < 0.05 (comparison with the untreated values). Bold values are significantly different from untreated values at the level of p < 0.05.

3.3. The Efficacy of Antidotes (Atropine, Trimedoxime, MB327) for Prevention of Tabun Lethality

The tabun results feature in Table 3. Times to death differed slightly between treatment groups. All deaths occurred within 6 h in mice given atropine and trimedoxime, atropine and the lower dose of MB327, and atropine with trimedoxime and MB327. Most mice died within the first hour. The average time to death within the first 6 h was 14.3 min for non-treated animals and 17.6 min for treated animals. With atropine alone, and with atropine in combination with the higher dose of MB327, some deaths occurred after 6 h. Thus, atropine increased the LD₅₀ of tabun 1.20-fold at 6 h but only 1.09-fold at 24 h. Atropine and the higher dose of MB327 increased it 1.52-fold at 6 h and only 1.32-fold at 24 h. Atropine and the lower dose of MB327 increased it only 1.20-fold, atropine and trimedoxime increased it 1.95-fold, and atropine and trimedoxime and the higher dose of MB327 increased it 2.06-fold. With atropine and the higher dose of MB327, the protection ratio increased compared to atropine alone, at both experimental end points but the differences were not significant. The efficacy of atropine and trimedoxime was higher than that of atropine and MB327 regardless of the dose of the latter and end point. A significant benefit of MB327 on the efficacy of atropine and trimedoxime was not observed.

Table 3. The effect of experimental endpoint on the protection provided against the lethal effects of tabun in mice.

| Treatment                        | LD₅₀ (µg/kg) ± 95% Confidence Limit—6 h | Protective Ratio A | LD₅₀ (µg/kg) ± 95% Confidence Limit—24 h | Protective Ratio A | Protective Ratio B |
|----------------------------------|----------------------------------------|--------------------|------------------------------------------|--------------------|--------------------|
| ——                              | 420.5 (370.8–470.2)                    | ——                | 420.5 (370.8–470.2)                      | ——                | ——                |
| Atropine                         | 504.2 (447.4–533.3)                    | 1.20              | 458.3 (405.2–494.0)                      | 1.09              | 1.10              |
| Atropine + trimedoxime           | 818.9 (774.2–866.2) *                  | 1.95              | 818.9 (774.2–866.2) *                    | 1.95              | 1.00              |
| Atropine + MB327 (lower dose)    | 503.7 (466.5–543.9)                    | 1.20              | 503.7 (466.5–543.9)                      | 1.20              | 1.00              |
| Atropine + MB327 (higher dose)   | 639.4 (492.2–822.3) *                  | 1.52              | 554.2 (472.7–602.9) *                    | 1.32              | 1.15              |
| Atropine + trimedoxime + MB327  | 866.0 (738.9–1017.5) *                 | 2.06              | 866.0 (738.9–1017.5) *                   | 2.06              | 1.00              |

* p < 0.05 (comparison with the untreated values). * p < 0.05 (comparison with the values treated with atropine alone). Bold values are significantly different from untreated values and values treated with atropine alone at the level of p < 0.05.
3.4. The Efficacy of Antidotes (Atropine, HI-6, MB327) for Prevention of Cyclosarin Lethality

The efficacies of the antidotes to cyclosarin appear in Table 4. A difference in distribution of times to death among treatment groups was not observed; all deaths occurred within the first 6 h. Most mice died within the first hour. The average time to death within the first 6 h was 9.3 min for non-treated animals and 12.5 min for treated animals. With atropine alone the LD$_{50}$ of cyclosarin increased 1.31-fold. In combination with HI-6 it increased by 3.15-fold, with the lower or higher dose of MB327 it increased it 1.24- or 1.34-fold, respectively, and with HI-6 and the higher dose of MB327 it increased it 3.12-fold. Atropine and the higher dose of MB327 produced a slightly increased therapeutic efficacy compared to atropine with the lower dose of MB327 but the difference was not significant. The efficacy of atropine and HI-6 was superior to that of atropine and MB327. A benefit of MB327 on the efficacy of atropine and HI-6 was not observed.

Table 4. The effect of experimental endpoint on the protection provided against the lethal effects of cyclosarin in mice.

| Treatment                  | LD$_{50}$ (µg/kg) ± 95% Confidence Limit—6 h | Protective Ratio A | LD$_{50}$ (µg/kg) ± 95% Confidence Limit—24 h | Protective Ratio A | Protective Ratio B |
|----------------------------|---------------------------------------------|--------------------|---------------------------------------------|--------------------|--------------------|
| ——                         | 248.4 (192.8–287.9) ——                        | ——                | 248.4 (192.8–287.9) ——                        | ——                | ——                |
| Atropine                   | 326.8 (254.9–417.7) 1.31                     | 326.8 (254.9–417.7) 1.31 | 326.8 (254.9–417.7) 1.31                     | 1.31               | 1.00               |
| Atropine + HI-6            | 782.9 (680.6–856.4) **x**                     | 3.15               | 782.9 (680.6–856.4) **x**                     | 3.15               | 1.00               |
| Atropine + MB327 (lower dose) | 309.1 (268.0–394.4) 1.24                     | 309.1 (268.0–394.4) 1.24 | 309.1 (268.0–394.4) 1.24                     | 1.24               | 1.00               |
| Atropine + MB327 (higher dose) | 333.4 (247.1–400.9) 1.34                     | 333.4 (247.1–400.9) 1.34 | 333.4 (247.1–400.9) 1.34                     | 1.34               | 1.00               |
| Atropine + HI-6 + MB327    | 775.9 (635.3–878.8) **x**                     | 3.12               | 775.9 (635.3–878.8) **x**                     | 3.12               | 1.00               |

*$p < 0.05$ (comparison with the untreated values). **$p < 0.05$ (comparison with the values treated with atropine alone). Bold values are significantly different from untreated values and values treated with atropine alone at the level of $p < 0.05$.

4. Discussion

Oximes are key components of nerve agent antidotes due to their capability to reactivate nerve agent-inhibited AChE. However, their therapeutic efficacy is restricted, as reactivation of inhibited AChE is not universally effective because all nerve agents and current oximes are generally ineffective in the central compartment due to their difficulty crossing the blood–brain barrier [4]. Generally, the reactivating efficacy of each oxime depends on the chemical structure of the nerve agent and it is not the same for all nerve agents studied. Therefore, one of the most effective oximes was chosen for each nerve agent (obidoxime for sarin, trimedoxime for tabun, and HI-6 for soman and cyclosarin [4,7,26,27]). Although obidoxime, used for the treatment of sarin poisoning, has a lower efficacy against sarin than the oxime HI-6 [26], it was used for sarin poisoning in this study due to the need to compare our results with previously published data where obidoxime was used for the treatment of sarin poisoning.

Additionally, anticholinergic drugs such as atropine cannot counter the overstimulation of nAChRs. Therefore, novel potential antidotes, based on bispyridinium non-oxime structures, were developed to mitigate the overstimulation of nAChRs and to reduce the therapeutic reliance on oxime-based reactivation of AChE in the treatment of nerve agent poisoning [12,29].

Several bispyridinium compounds have been shown to counter the acute toxicity of nerve agents [12,21–23,30]. Their efficacy hinges on modulating nAChRs at the ion channel, orthosteric ACh binding sites, or both [31,32]. One of the most promising is MB327. It has been shown to have a positive therapeutic effect due to a non-competitive antagonistic action at muscle type nAChRs and has been found to have a positive allosteric activity at muscle and neuronal AChRs [20,33,34]. MB227 has been characterized as a re-sensitizer of
the desensitized nAChR. MB327 is thereby capable of restoring its functional activity and restoring nerve agent-induced irreversibly disrupted neurotransmission at the neuromuscular junctions. The re-sensitizing effect of MB327 is probably based on its positive allosteric activity, as was repeatedly demonstrated [32,35]. Two putative binding sites were found for MB327. Both sites are located inside the channel: one in the extracellular domain between the γ and α subunits, and the other between β and δ subunits in the transmembrane region [17,33,34]. By comparison, MB327 does not interact with the orthosteric ACh binding sites [16]. It is known that conventional nAChR antagonists have a low therapeutic index between sufficient antagonism and muscle paralysis and, therefore, they have a negative impact on respiration However, MB327, which acts as a re-sensitizer of the desensitized nAChR, has a low impact on respiration when administered at recommended doses [13]. In addition, MB327, like other bispyridinium non-oxime compounds, is a charged polar species. It has a high aqueous solubility and comparatively low hydrophobicity. It is therefore expected to exert its biological action mainly in the periphery rather than in the brain, and to have a low capacity to cross the blood–brain barrier.

In the present study, the significant benefit of MB327 for the therapeutic efficacy of standard antidotal treatment of nerve agent poisoning was not shown. To determine the optimal potential of antidotes, a pharmacologically relevant time following intoxication should be selected based on the pharmacokinetics and mechanisms of action of the drugs tested. An effective concentration of MB327 in the blood and at key nicotinic synapses in tissues is required for nicotinic antagonism and consequent protection. Due to the predicted rapid elimination of MB327 from the body [23], a decrease in the efficacy of MB327 from 6 to 24 h was anticipated. However, a slight reduction in the efficacy of MB327 from 6 to 24 h was only observed for the higher dose of MB327 for soman and tabun intoxication.

To compare the influence of the end point on the therapeutic efficacy of MB327 with other MB antinicotinics, the analogue MB408 showed a higher decrease in its efficacy from 6 to 24 h in the case of intoxication with nerve agents, especially sarin and soman [36]. Generally, the changes in protection ratio seen with atropine with MB327 at 6 h compared to 24 h were small, were only observed for the higher MB327 dose, and were not statistically significant. In contrast, the effects of MB327 in guinea pigs showed a very marked increase in protection at a 6 h compared to a 24 h end point [37]. This disparity may reflect MB327 pharmacokinetic differences between the mouse and guinea pig: in size, absorption, distribution, metabolism and elimination.

The present and previous studies in mice [36] and in guinea pigs [37] demonstrate that earlier experimental end points can show that certain treatments can provide increased protection against acute intoxication by nerve agents. This is also supported theoretically by the reversible, pharmacological mechanism of action of certain antidotes, and therefore a reliance on their pharmacokinetics, ensuring that therapeutically effective drug concentrations are maintained. Importantly, then, the shorter experimental end point may reduce the risk of falsely rejecting effective treatments, particularly if these are intended for immediate, first-aid treatment of nerve agent casualties. Our study has limitations because only one animal species and one end point (besides the standard 24 h) were used. Due to species differences, especially in the pharmacokinetics of MB327 (and analogues), the end point chosen should be matched to the animal species studied, as different species or end points may provide different results.

5. Conclusions

Although MB327 may provide limited benefit for the treatment of nerve agent poisoning in the absence of an oxime, the data from the evaluation of the therapeutic efficacy of MB327 in this particular study do not support the presumption that this non-competitive antinicotinic may significantly benefit the standard antidotal treatment (atropine + oxime) of nerve agent intoxication, at least in mice. Its effectiveness did not approach any of the oximes studied in this animal species. Therefore, atropine and an oxime should continue to
be the core elements of treatment. As only a negligible beneficial impact of the compound MB327 was observed, novel compounds with similar action to MB327 but which exhibit better nicotinic selectivity and increased antinicotinic efficacy should be developed.

Author Contributions: J.K.: conceptualization; formal analysis; writing—original draft preparation; C.M.T.: conceptualization; writing—review and editing; M.B.: synthesis of MB327; formal analysis; A.C.G.: investigation, writing—review and editing; J.E.H.T.: investigation; supervision. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Ministry of Defence of the Czech Republic under the grant entitled the “Long-term organization development plan—Medical Aspects of Weapons of Mass Destruction” of the Faculty of Military Health Sciences Hradec Kralove, University of Defence, Czech Republic.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the Faculty of Military Health Sciences in Hradec Kralove, Czech Republic (protocol code MO 80162/2021-1457 and date of approval 18 March 2021).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data from this study are available on request from the corresponding author. They are not publicly available due to ethical restrictions.

Acknowledgments: The authors thank Eng. Jana Hatlapatkova and Bc. Iveta Kaderabkova for valued technical assistance and Rebecca L. Williams for checking that MB327 was pure by NMR spectroscopy.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Hrvat, N.M.; Kovarik, Z. Counteracting poisoning with chemical warfare agents. *Arh. Hig. Rada Toksikol.* 2020, 71, 266–284. [CrossRef] [PubMed]
2. Tattersall, J.E.H. Anticholinesterase toxicity. *Curr. Opin. Physiol.* 2018, 4, 49–56. [CrossRef]
3. Leibson, T.; Lifshitz, M. Organophosphate and carbamate poisoning: Review of the current literature and summary of clinical and laboratory experience in southern Israel. *Isr. Med. Assoc. J.* 2008, 10, 767–770. [PubMed]
4. Baig, J. Organophosphates/nerve agent poisoning: Mechanism of action, diagnosis, prophylaxis, and treatment. *Adv. Clin. Chem.* 2004, 38, 151–216.
5. Colović, M.B.; Krstić, D.Z.; Lazarević-Pašti, T.D.; Bondžić, A.M.; Vasić, V.M. Acetylcholinesterase inhibitors: Pharmacology and toxicology. *Curr. Neuropharmacol.* 2013, 11, 315–335. [CrossRef]
6. Marrs, T.C.; Rice, P.; Vale, J.A. The role of oximes in the treatment of nerve agent poisoning in civilian casualties. *Toxical. Rev.* 2006, 25, 297–323. [CrossRef]
7. Jokanović, M. Structure-activity relationship and efficacy of pyridinium oximes in the treatment of poisoning with organophosphorus compounds: A review of recent data. *Curr. Top. Med. Chem.* 2012, 12, 1775–1789. [CrossRef]
8. Timperley, C.M.; Tattersall, J.E.H. Toxicology and medical treatment of organophosphorus compounds. In *Best Synthetic Methods—Organophosphorus (V) Chemistry*; Timperley, C.M., Ed.; Elsevier: Oxford, UK, 2015; pp. 33–89.
9. Sharma, R.; Gupta, B.; Singh, N.; Acharya, J.R.; Musilek, K.; Kuca, K.; Ghosh, K.K. Development and structural modifications of cholinesterase reactivators against chemical warfare agents in last decade: A review. *Mini Rev. Med. Chem.* 2015, 15, 58–72. [CrossRef]
10. Timperley, C.M.; Forman, J.E.; Abdollahi, M.; Al-Amri, A.S.; Baulig, A.; Benachour, D.; Borrett, V.; Cariño, F.A.; Geist, M.; Gonzalez, D.; et al. Advice on assistance and protection provided by the Scientific Advisory Board of the Organisation for the Prohibition of Chemical Weapons: Part 1. On medical care and treatment of injuries from nerve agents. *Toxicology* 2019, 415, 56–69. [CrossRef]
11. Timperley, C.M.; Abdollahi, M.; Al-Amri, A.S.; Baulig, A.; Benachour, D.; Borrett, V.; Cariño, F.A.; Geist, M.; Gonzalez, D.; Kane, W.; et al. Advice on assistance and protection provided by the Scientific Advisory Board of the Organisation for the Prohibition of Chemical Weapons: Part 2. On preventing and treating health effects from acute, prolonged, and repeated nerve agent exposure, and the identification of medical countermeasures able to reduce or eliminate the longer term health effects of nerve agents. *Toxicology* 2019, 413, 13–23.
12. Turner, S.R.; Chad, J.E.; Price, M.E.; Timperley, C.M.; Bird, M.; Green, A.C.; Tattersall, J.E.H. Protection against nerve agent poisoning by a noncompetitive nicotinic antagonist. *Toxicol. Lett.* 2011, 206, 105–111. [CrossRef] [PubMed]
13. Sheridan, R.D.; Smith, A.P.; Turner, S.R.; Tattersall, J.E.H. Nicotinic antagonists in the treatment of nerve agent intoxication. *J. R. Soc. Med.* 2006, 98, 114–115. [CrossRef]
14. McDonough, J.H.; Shih, T.M. Atropine and other anticholinergic drugs. In Chemical Warfare Agents: Toxicology and Treatment, 2nd ed.; Marrs, T.C., Maynard, R.I., Sidell, F.R., Eds.; John Wiley & Sons Ltd.: Chichester, UK, 2007; pp. 287–303.

15. Tattersall, J.E.H. Ion channel blockade by oximes and recovery of diaphragm muscle from soman poisoning in vitro. Br. J. Pharmacol. 1993, 108, 1006–1015. [CrossRef] [PubMed]

16. Niessen, K.V.; Tattersall, J.E.H.; Timperley, C.M.; Bird, M.; Green, A.C.; Seeger, T.; Thiermann, H.; Worek, F. Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs). Toxicol. Lett. 2011, 206, 100–104. [CrossRef] [PubMed]

17. Wein, T.; Höfner, G.; Rappenglück, S.; Sichler, S.; Niessen, K.V.; Seeger, T.; Worek, F.; Thiermann, H.; Wanner, K.T. Searching for putative binding sites of the bispyridinium compound MB327 in the nicotinic acetylcholine receptor. Toxicol. Lett. 2018, 293, 184–189. [CrossRef] [PubMed]

18. Sichler, S.; Höfner, G.; Rappenglück, S.; Wein, T.; Niessen, K.V.; Seeger, T.; Worek, F.; Thiermann, H.; Painter, F.F.; Wanner, K.T. Development of MS binding assays targeting the binding site of MB327 at the nicotinic acetylcholine receptor. Toxicol. Lett. 2020, 340, 114–122. [CrossRef] [PubMed]

19. Epstein, M.; Bali, K.; Piggot, T.J.; Green, A.C.; Timperley, C.M.; Bird, M.; Tattersall, J.E.H.; Bermudez, I.; Biggin, P.C. Molecular determinants of binding of non-oxime bispyridinium nerve agent antidotes to the adult muscle nAChR. Toxicol. Lett. 2021, 340, 1–10. [CrossRef] [PubMed]

20. Scheffel, C.; Niessen, K.V.; Rappenglück, S.; Wanner, K.T.; Thiermann, H.; Worek, F.; Seeger, T. Counteracting desensitization of human α7-nicotinic acetylcholine receptors with bispyridinium compounds as an approach against organophosphorus poisoning. Toxicol. Lett. 2018, 293, 149–156. [CrossRef]

21. Timperley, C.M.; Bird, M.; Green, A.C.; Price, M.E.; Chad, J.E.; Turner, S.R.; Tattersall, J.E.H. 1′-(Propylene-1,3-diyl)bis(4-tert-butylpyridinium) di(methane sulfonate) protects guinea pigs from soman poisoning when used as part of a combined therapy. Med. Chem. Commun. 2012, 3, 352–356. [CrossRef]

22. Kassa, J.; Pohanka, M.; Timperley, C.M.; Bird, M.; Green, A.C.; Tattersall, J.E.H. Evaluation of the benefit of the bispyridinium compound MB327 for the antidotal treatment of nerve-agent poisoned mice. Toxicol. Mech. Methods. 2016, 26, 334–339. [CrossRef]

23. Price, M.E.; Doxx, C.J.; Rice, H.; Fairhall, S.J.; Poole, S.J.C.; Bird, M.; Whiley, L.; Flint, D.P.; Green, A.C.; Timperley, C.M.; et al. Pharmacokinetic profile and quantitation of protection against soman poisoning by the antinicotinic compound MB327 in the guinea-pig. Toxicol. Lett. 2016, 244, 154–160. [CrossRef] [PubMed]

24. Jun, D.; Kuca, K.; Stodulka, P.; Koleckar, V.; Dolezal, B.; Simon, P.; Veverka, M. HPLC analysis of HI-6 dichloride and dimethanesulfonate—antidotes against nerve agents and organophosphorus pesticides. Anal. Lett. 2007, 40, 2783–2787. [CrossRef]

25. Tallarida, R.; Murray. R Manual of Pharmacological Calculation with Computer Programs; Springer: New York, NY, USA, 1987.

26. Kassa, J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agent. J. Toxicol. Clin. Toxicol. 2002, 40, 803–816. [CrossRef] [PubMed]

27. Antonijevic, B.; Stojiljkovic, P. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin. Med. Res. 2007, 5, 71–82. [CrossRef]

28. Sevelova, L.; Kuca, K.; Krejčova-Kunesova, G. Antidotal treatment of GF-agent intoxication in mice with bispyridinium oximes. Toxicology 2005, 207, 1–6. [CrossRef]

29. Ring, A.; Strom, B.O.; Turner, S.R.; Timperley, C.M.; Bird, M.; Green, A.C.; Chad, J.; Worek, F.; Tattersall, J.E.H. Bispyridinium compounds inhibit both muscle and neuronal nicotinic acetylcholine receptors in human cell lines. PLoS ONE 2015, 10, e0135811. [CrossRef]

30. Kassa, J.; Timperley, C.M.; Bird, M.; Williams, R.L.; Green, A.C.; Tattersall, J.E.H. Some benefit from non-oximes MB408, MB442 and MB444 in combination with the oximes HI-6 or obidoxime and atropine in antidoting sarin or cyclosarin poisoned mice. Toxicology 2018, 408, 95–100. [CrossRef]

31. Niessen, K.V.; Seeger, T.; Tattersall, J.E.H.; Timperley, C.M.; Bird, M.; Green, A.C.; Thiermann, H.; Worek, F. Affinities of bispyridinium non-oxide compounds to [3H]epibatidine binding sites of Torpedo californica nicotinic acetylcholine receptors depend on linker length. Chem. Biol. Interact. 2013, 206, 545–554. [CrossRef]

32. Seeger, T.; Eichhorn, M.; Lindner, M.; Niessen, K.V.; Tattersall, J.E.H.; Timperley, C.M.; Bird, M.; Green, A.C.; Thiermann, H.; Worek, F. Restoration of soman-blocked neuromuscular transmission in human and rat muscle by the bispyridinium non-oxide MB327 in vitro. Toxicology 2012, 294, 80–84. [CrossRef]

33. Rappenglück, S.; Sichler, S.; Höfner, G.; Wein, T.; Niessen, K.V.; Seeger, T.; Painter, F.F.; Worek, F.; Thiermann, H.; Wanner, K.T. Synthesis of a series of structurally diverse MB327 derivatives and their affinity characterization at the nicotinic acetylcholine receptor. ChemMedChem 2018, 13, 1806–1816. [CrossRef]

34. Rappenglück, S.; Sichler, S.; Höfner, G.; Wein, T.; Niessen, K.V.; Seeger, T.; Painter, F.F.; Worek, F.; Thiermann, H.; Wanner, K.T. Synthesis of a series of non-symmetric bispyridinium and related compounds and their affinity characterization at the nicotinic acetylcholine receptor. ChemMedChem 2018, 13, 2653–2663. [CrossRef] [PubMed]

35. Niessen, K.V.; Muschik, S.; Langguth, F.; Rappenglück, S.; Seeger, T.; Thiermann, H.; Worek, F. Functional analysis of Torpedo California nicotinic acetylcholine receptors in multiple activation states by CCM-based electrophysiology. Toxicol. Lett. 2016, 247, 1–10. [CrossRef] [PubMed]
36. Kassa, J.; Timperley, C.M.; Bird, M.; Green, A.C.; Tattersall, J.E.H. Influence of experimental end point on the therapeutic efficacy of the antinicotinic compounds MB408, MB422 and MB444 in treating nerve agent poisoned mice—A comparison with oxime-based treatment. *Toxicol. Mech. Methods* 2020, 30, 703–710. [CrossRef] [PubMed]

37. Price, M.E.; Whitmore, C.L.; Tattersall, J.E.H.; Green, A.C.; Rice, H. Efficacy of the antinicotinic compound MB327 against soman poisoning—Importance of experimental end point. *Toxicol. Lett.* 2018, 293, 167–171. [CrossRef] [PubMed]